Mineralys Therapeutics, Inc. 8-K

What Happened
Mineralys Therapeutics (MLYS) announced on June 2, 2026 that it entered into a fourth amendment to its lorundrostat license with Tanabe Pharma and closed a senior secured term loan facility. Under the amendment, Tanabe amended and restated the lorundrostat license to grant Mineralys an exclusive, worldwide, royalty-free, sublicensable, perpetual and irrevocable license; Mineralys will no longer owe royalties to Tanabe. The company agreed to a one-time cash payment of $200.0 million to Tanabe and up to $100.0 million in additional commercial milestone payments (the “New Milestones”), and Tanabe will assign its rights in the licensed IP pursuant to a forthcoming termination agreement. Separately, on June 2, 2026 Mineralys closed a five-year senior secured term loan facility providing up to $500.0 million in term loans, with $100.0 million (Tranche A) funded at closing.

Key Details

• License amendment: one-time payment $200.0M now, plus up to $100.0M in New Milestones; Mineralys will have remaining contingent commercial milestone obligations of up to $255.0M (upon first commercial sale and sales targets) and up to $10.0M for a second indication. No future royalty payments to Tanabe. Right of first negotiation for Japan survives.
• Loan facility: up to $500.0M total in four tranches — Tranche A $100.0M funded 6/2/2026; Tranche B $150.0M (must be drawn by 4/30/2027 subject to FDA approval of lorundrostat NDA); Tranche C $150.0M (available until 12/14/2028, subject to Tranche B approval and sales milestones); Tranche D $100.0M (available until 6/14/2029, subject to C draw and sales milestones).
• Economics and term: five-year maturity (6/3/2031); interest = 3-month SOFR (3.25% floor) + 5.50%, payable quarterly; 2.00% funding fee on each tranche at funding; prepayment subject to make-whole/exit fees and mandatory prepayments if Tranche B approval not met by specified dates.
• Security and covenants: loans secured by substantially all assets, including IP; affirmative and restrictive covenants, financial covenants (minimum liquidity until Tranche B approval and a trailing-12-month net product revenue covenant starting FY2028 with quarterly tests beginning 3/31/2029); customary events of default and remedies.

Why It Matters
These transactions materially change Mineralys’ finance and rights around lorundrostat. The license amendment eliminates royalty obligations and secures perpetual ownership and commercialization rights (subject to Japan negotiation rights), but creates large upfront and milestone cash obligations (immediate $200M plus potential additional milestone payments). The $500M secured loan provides significant near- and mid-term funding capacity — including $100M funded now and additional tranches tied to FDA approval and sales — but adds secured debt, covenants and restrictions on the company’s operations and assets that investors should monitor. Key near-term triggers to watch: FDA NDA timing (affects Tranche B availability), milestone payments on change-of-control or commercialization, and compliance with the loan’s liquidity and revenue covenants.